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mg. every 6 hours for 10 days, dur-
ing which time the surgeon suspended 
surgical procedures. Recommenda-
tions were made regarding infection 
prevention practices; these were un-
dertaken by the surgeon.
Although soft tissue infection fol-
lowing sclerotherapy may be under-
reported, large case series have not 
noted this complication in the past 
(2,3); this ﬁ   nding suggests that any 
soft tissue infection following sclero-
therapy should be investigated. These 
cases highlight the need for vigilance 
when considering infection control for 
minor procedures that take place out-
side of the support of hospital-based 
infection control services. 
Soft tissue infections as com-
plications following varicose vein 
sclerotherapy appear to be rare (1–3). 
The Australian Aethoxysklerol study 
reported no cellulitis in 16,804 legs 
injected with the sclerosing agent, and 
superﬁ  cial thrombophlebitis occurred 
at a rate of 0.08% at 2-year review 
(2). Likewise, a multicenter registry 
with 22 European phlebology clinics 
reported no cellulitis or necrotizing 
fasciitis in 12,173 sessions (3). 
Similarly, surgical site infections 
with Group A Streptococcus spp. are 
uncommon. A multicenter survey of 72 
centers worldwide reported all β-he-
molytic Streptococcus spp. (including 
group A and group G) accounted for 
<5% of infections (4), while surveil-
lance in the 1990s by Centers for Dis-
ease Control and Prevention reported 
<1% of all surgical wound infections 
was caused by group A Streptococcus 
spp. (5). A Canadian study reported 
invasive group A Streptococcus infec-
tions following surgery in 1.1 cases 
per 100,000 admissions (6). Outbreaks 
have been infrequently described (5,7–
10), and sources of colonization range 
from throat to anus and vagina. 
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To the Editor: Streptococcus suis 
is an important zoonotic pathogen for 
swine and humans. Among 33 sero-
types, serotype 2 is more frequently 
isolated from diseased pigs than other 
serotypes (1). However, not all sero-
type 2 strains are virulent, and degree 
of virulence varies among strains (2). 
Previous studies have reported sev-
eral S. suis putative virulence factors, 
including the polysaccharide capsule, 
the muramidase-released protein, the 
extracellular factor, and suilysin (3–5). 
Some of these factors have been used 
as virulence-associated markers, and 
the association of the factors of S. suis 
isolates with virulence or clinical back-
ground has been suggested in Europe 
(2,5). However, because many viru-
lent isolates lacking these factors have 
also been isolated from clinical cases 
in Canada (6), they cannot be used as 
virulence markers in North America.
Recent analysis of S. suis iso-
lates by multilocus sequence typing 
(MLST) suggested the association of 
some clonal groups with particular 
clinical manifestations. That is, most 
invasive isolates belonged to the se-
quence type (ST) 1 complex, while the 
ST27 and ST87 complexes were found 
to include a higher proportion of lung 
isolates (7). Although S. suis has been 
prevalent worldwide, the geographic 
location of the isolates used so far was 
mainly Europe, North America, and 
East Asia (7–9). Moreover, the clonal 
association with virulence of S. suis 
has been discussed mainly on the ba-
sis of clinical and experimental data 
in swine (7). In this report, to broaden 
understanding of the population struc-
ture of S. suis as a zoonotic agent, we 
characterize 20 S. suis isolates (Table) 
recovered from humans in Thailand in 
1998–2002.
Serotyping by coagglutination 
tests showed that 19 of the 20 isolates 
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maining 1 (MNCM07) was serotype 
14. MLST analysis resolved the 20 
isolates into 8 STs (Table). By us-
ing eBURST (http://eburst.mlst.net), 
we assigned 4 isolates (MNCM01, 
MNCM06, MNCM07, and MNCM16) 
from 1 case of endocarditis and 3 cas-
es of meningitis to the ST1 complex. 
The remaining isolates were assigned 
to the ST27 complex with a less-
stringent group deﬁ  nition (Table), al-
though ST101 (MNCM21) and ST104 
(MNCM50) shared only 2 alleles with 
ST27 and were incorporated into this 
complex by a chaining effect. Regard-
ing the clinical cases from which the 
ST27 complex isolates were recovered, 
the patients had meningitis, endocardi-
tis, septicemia, septic shock, diarrhea, 
and respiratory involvement. The 2 ST 
complexes both contained isolates from 
deceased patients (Table). 
All the isolates assigned to the 
ST1 complex were positive for the 
suilysin gene sly, the extracellular fac-
tor gene epf or its variant, and the mu-
ramidase-released protein gene mrp 
or its variant. With the exception of 
MNCM21 and MNCM50, which had 
only sly, all isolates classiﬁ  ed into the 
ST27 complex were negative for sly 
and epf but positive for mrp or its vari-
ant. These results showed the congru-
ence between STs and the virulence-
associated gene proﬁ   les and further 
support the usefulness of MLST for 
epidemiologic studies of S. suis.
Of the 3 major clonal complexes 
identiﬁ  ed so far in S. suis (ST1, ST27, 
and ST87), the ST1 complex particu-
larly attracts considerable public atten-
tion as a clonal group that may have 
the potential for a higher degree of 
virulence than the others (7), and most 
(96%) of the human isolates investi-
gated so far, including ST7 isolates, 
which caused the largest outbreak in 
China, belong to the ST1 complex 
(7–9). In this study, although no ST7 
isolate was found, 4 isolates were as-
signed to the ST1 complex. This fur-
ther conﬁ  rmed the gravity of the ST1 
complex not only for swine industries 
but also for public health.
In contrast to the ST1 complex, 
only 4 human clinical isolates have 
so far been reported to belong to the 
ST27 complex. Three of the 4 are iso-
lates from Canada that belong to ST25 
Table. Epidemiologic data of Streptococcus suis isolates from patients in Thailand, 1998–2002* 
Isolate no.† 
Year of 
isolation Site of isolation  Virulence-associated genes‡§ Serotype  Diseases and symptoms 
ST
(ST complex)
MNCM01 2000 Blood cps2J+/sly+/epf+/mrp+2 ¶ Endocarditis 1 (1)
MNCM06 2000 Blood, CSF  cps2J+/sly+/epf+/mrp+ 2 Neck stiffness, deafness 
(meningitis)
1 (1) 
MNCM16 2000 CSF cps2J+/sly+/epf+/mrp+ 2 Neck stiffness (meningitis)  1 (1) 
MNCM07 2000 Blood, CSF  cps1J+/sly+/epf*/mrpS+ 14 Neck stiffness (meningitis), 
death
11 (1) 
MNCM04 2000 Blood cps2J+/sly–/epf–/mrp**+ 2 Neck stiffness, deafness 
(meningitis)
25 (27)# 
MNCM10 2000 Blood cps2J+/sly–/epf–/mrp**+ 2 Septicemia 25 (27)# 
MNCM24 2001 Blood cps2J+/sly–/epf–/mrp**+ 2¶ Endocarditis 25 (27)# 
MNCM26 2001 Blood cps2J+/sly–/epf–/mrp**+ 2 Endocarditis, deafness 
(meningitis)
25 (27)# 
MNCM51 2002 Blood cps2J+/sly–/epf–/mrp**+ 2 Septicemia, diarrhea, death  25 (27)# 
MNCM55 2002 Blood cps2J+/sly–/epf–/mrp**+ 2 Septic shock, death  25 (27)# 
LPH4 2001 Blood cps2J+/sly–/epf–/mrp**+ 2 Septicemia, diarrhea  25 (27)# 
LPH12 2002 Blood cps2J+/sly–/epf–/mrp**+ 2 Septic shock, death  25 (27)# 
MNCM43 2002 Blood cps2J+/sly–/epf–/mrp+ 2 Endocarditis 28 (27) 
MNCM21 1998 CSF cps2J+/sly+/epf–/mrp– 2 Meningitis 101 (27)# 
MNCM25 2001 Blood cps2J+/sly–/epf–/mrp**+ 2 Neck stiffness (meningitis), 
diarrhea, death 
102 (27)# 
MNCM54 2002 Blood cps2J+/sly–/epf–/–mrp**+ 2 Neck stiffness (meningitis), 
diarrhea
102 (27)# 
MNCM33 2002 Blood, CSF  cps2J+/sly–/epf–/mrp**+ 2 Neck stiffness (meningitis)  103 (27)# 
LPH3 2001 Blood cps2J+/sly–/epf–/mrp**+ 2 Meningitis 103 (27)# 
LPH5 2001 Blood cps2J+/sly–/epf–/mrp**+ 2 Septicemia 103 (27)# 
MNCM50 2002 Blood cps2J+/sly+/epf–/mrp– 2 Pulmonary edema, death  104 (27)# 
*ST, sequence type; CSF, cerebrospinal fluid. 
†Isolates with MNCM number and LPH number were isolated from patients at Maharaj Nakorn Chiang Mai Hospital and Lamphun Hospital, Thailand, 
respectively. 
‡Virulence-associated gene profiling was done as described previously (10). cps1J and cps2J, serotype 1 (and 14) and 2 (and 1/2) specific genes, 
respectively, involved in the capsular biosynthesis; sly, suilysin gene; epf, extracellular factor gene; mrp, muraminidase-released protein gene; +, positive; 
–, negative. 
§epf*, an epf variant that produces an  3,000-bp fragment by PCR with primers described previously (10); mrp** and mrpS, mrp variants that produce 
 1,800-bp and  750-bp fragments, respectively, by PCR with primers described previously (10). 
¶Coagglutination reaction using anti-serotype 2 serum was weak. 
#ST25, ST101, ST102, ST103, and ST104 belong to the ST27 complex, only with a less-stringent approach that defines an ST complex by sharing of 
alleles at >5 of the 7 loci. 
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assigned to ST28 (8). Unlike in previ-
ous reports, 80% of the human clinical 
isolates (16 isolates) characterized in 
this study were assigned to the ST27 
complex. Although previous studies 
suggested that members of the ST27 
complex may have lower potential to 
cause invasive diseases in swine (7), 
all the isolates were isolated from 
blood or cerebrospinal ﬂ   uid of the 
patients, suggesting a high degree of 
invasiveness (Table). Because it is 
unknown whether the ST27 complex 
is also dominant among isolates from 
diseased pigs in Thailand, future sur-
veillance  will be necessary to know 
the situation in pigs. However, our 
data indicate that the ST27 complex 
is another clonal group that should be 
assessed for its importance for human 
infection. Because mrp,  epf, and sly 
are not appropriate as virulence mark-
ers for the ST27 complex members, 
development of novel virulence mark-
ers will be needed for efﬁ  cient dis-
crimination of S. suis strains virulent 
for humans. 
This study made use of the Strepto-
coccus suis Multilocus Sequence Typing 
website (http://ssuis.mlst.net); this site is 
hosted at Imperial College and develop-
ment is funded by the Wellcome Trust. The 
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To the Editor:  Streptococcus 
suis,  commensal and opportunistic 
pathogens of swine, and prevalent 
zoonotic agents worldwide, are α-he-
molytic gram-positive cocci with 35 
different serotypes (1). In humans, S. 
suis infection has been associated with 
bacterial meningitis, septic shock, ar-
thritis, pneumonia, endocarditis, en-
dophthalmitis, and spontaneous bacte-
rial peritonitis (2,3). Most at risk are 
those who handle or eat undercooked 
pork, e.g., farm workers, butchers, 
and slaughterhouse workers (4). Most 
cases have been reported in Europe or 
Southeast Asia (2,3). Meningitis, ﬁ  rst 
recognized in 1968 in Denmark (1), is 
the most common clinical manifesta-
tion of human infection with S. suis. A 
case of S. suis meningitis in a pig farm-
er was reported in the United States 
(5). Here, we describe another case in 
a 60-year-old man from San Francisco 
who had consumed raw pork while 
traveling in the Philippines.
In June 2003, this man became 
ill with fever, diaphoresis, headache, 
nausea, and anorexia. He had just re-
turned from a 7-month vacation in the 
Philippines. Three days after symp-
toms onset, his physician prescribed 
doxycycline. Symptoms continued 
and he was admitted to a local hospi-
tal 5 days later with a fever of 38.9°C, 
nuchal rigidity, headache, and general 
malaise. 
The patient described no recent 
contact with sick persons; past medical 
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